An ongoing clinical trial, NCT04599140, is examining the potential benefits of combined treatment with nivolumab and the CXCR1/2-receptor antagonist SX-682 in patients with microsatellite-stable CRC [50]. The gene discussed is CXCR1; the disease is colorectal carcinoma.